| Literature DB >> 23788977 |
Anna Daria Janiszewska1, Sławomir Poletajew, Aleksander Wasiutyński.
Abstract
Renal cell carcinoma (RCC) comprises 3-4% of all malignant tumours among adults in Poland. Spontaneous regression of RCC is a rare but well-known phenomenon. Its frequency is estimated to be approximately 1% and a large part of the percentage is accounted for by the regression of pulmonary metastases in the course of clear type of RCC treatment. We searched PubMed, Embase and SciVerse Scopus databases, identifying 59 case reports of spontaneous regression of RCC. Those medical histories come from reports from around the world and date back up to 40 years. This review includes their analysis as well as description of possible explanations of this phenomenon postulated by different authors, including both misdiagnosis and immunological reactions. This study indicates that reliable diagnostics and reporting of all the cases of spontaneous regression play a key role, as this is the only method which enables a better perspective in understanding this issue.Entities:
Keywords: kidney cancer; metastasis; neoplasm regression; renal cell carcinoma; spontaneous remission
Year: 2013 PMID: 23788977 PMCID: PMC3685371 DOI: 10.5114/wo.2013.34613
Source DB: PubMed Journal: Contemp Oncol (Pozn) ISSN: 1428-2526
Summary of all reported cases of spontaneous regression of RCC from 1971 to 2011
| Type of regression | Organs | Number of reports | Number of cases |
|---|---|---|---|
| Regression of primary tumour | kidney | 4 | 5 |
| Delayed metastases | lungs | 5 | 5 |
| pancreas | 1 | 1 | |
| Regression of metastases | lungs | 27 | 30 |
| lungs, adrenal gland | 1 | 1 | |
| lungs, bones | 1 | 1 | |
| lungs, brain | 1 | 1 | |
| lungs, pleura | 1 | 1 | |
| lungs, scalp | 1 | 1 | |
| liver | 4 | 4 | |
| bones | 2 | 2 | |
| bones, liver | 1 | 1 | |
| choroid | 2 | 2 | |
| pleura | 2 | 2 | |
| brain | 1 | 1 | |
| pancreas | 1 | 1 | |
|
|
|
|
Fig. 1The most frequently affected organs in metastatic RCC
Fig. 2The role of the immune response in tumour rejection